Mersana Therapeutics is a clinical stage biopharmaceutical company focused on developing antibody drug conjugates (ADCs) for cancer patients. Co.'s platforms including Dolaflexin and Dolasynthen, deliver its auristatin DolaLock payload, as well as Immunosynthen, which delivers its stimulator of interferon genes (STING) agonist ImmunoLock payload. Co.'s product candidates include: upifitamab rilsodotin (UpRi), which is a Dolaflexin ADC targeting NaPi2b, an antigen expressed in ovarian cancer and other cancers; and XMT-1592, which is a Dolasynthen ADC targeting NaPi2b-expressing tumor cells. The MRSN YTD return is shown above.
The YTD Return on the MRSN YTD return page and across the coverage universe of our site,
is a measure of the total return for a given investment year-to-date for the current calendar year
(up to the end of prior trading session). Arguably, choosing the current calendar year for a measurement
period is on the one hand completely arbitrary, but on the other hand a year-to-date look can be extremely
useful in the context of our country's tax system which taxes gains and income on a calendar year basis.
Thus, researching Year-To-Date Returns is good practice for investors — whether MRSN YTD return or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's YTD return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the MRSN YTD return calculation (with any dividends reinvested as applicable), and to provide a
coverage universe of many stocks and ETFs to be able to compare YTD returns.
|